TOKYO, May 20 (Pulse News Wire) – StemCell Institute (7096.T) announced today that its board of directors held on May 20 decided on the candidates for directors and alternate auditors for the 27th regular shareholders' meeting scheduled for June 24, 2026. The current four directors, including three outside directors, will complete their terms upon the conclusion of the shareholders' meeting.
The company plans to nominate four new directors, two of whom will be outside directors. As a result, the ratio of outside directors among officers is expected to be approximately [NUM_0]% and the female director ratio approximately [NUM_1]%. StemCell Institute recognizes governance as a key management issue and emphasizes high-quality discussions and swift decision-making during board meetings while strengthening management systems and promoting diversity in talent. Newly appointed CFO Kei Kayano joined the company in June 2025 and was promoted to Executive Officer and Chief Financial Officer in August 2025.
She currently serves as the Director of Finance and Accounting Management Department. In addition, the company nominated Sakai Kazuo as an alternate auditor candidate. Sakai, born on March 4, 1947, has extensive experience, having worked at Kobayashi Corporation since April 1969 and joining the company in June 1999. He served as President until July 2005 and became an auditor in February 2019, subsequently becoming a consultant in June 2023.
His appointment as an alternate auditor is subject to approval by the audit committee and can be canceled by the board's resolution with the consent of the audit committee prior to his assumption of office.
🟢 Confidence: High AI-translated content.